Scientists are working on a benchmark for  efficacy that would allow drugmakers to conduct smaller, speedier human trials to get them to market and address a huge global vaccine shortage.

via @Reuters 
https://t.co/l5BnV3XiUa https://t.co/VrPEkfrkBo